| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | USWM LLC | 4441 SPRINGDALE RD | LOUISVILLE | KY | 40241-1086 | JEFFERSON | USA | UG3DA061620 | Registration Development Program for LUCEMYRA (Lofexidine) Label Expansion for Opioid Withdrawal Treatment in Adolescents | 001 | 1 | NIH | 3/18/2025 | $0 |
| | 2025 | 2024 | USWM LLC | 4441 SPRINGDALE RD | LOUISVILLE | KY | 40241-1086 | JEFFERSON | USA | UG3DA061620 | Registration Development Program for LUCEMYRA (Lofexidine) Label Expansion for Opioid Withdrawal Treatment in Adolescents | 000 | 1 | NIH | 10/9/2024 | $0 |
| | 2025 | 2024 | USWM LLC | 4441 SPRINGDALE RD | LOUISVILLE | KY | 40241-1086 | JEFFERSON | USA | UG3DA061620 | Registration Development Program for LUCEMYRA (Lofexidine) Label Expansion for Opioid Withdrawal Treatment in Adolescents | 002 | 1 | NIH | 4/2/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $2,916,742 ) |
| | 2024 | 2024 | USWM LLC | 4441 SPRINGDALE RD | LOUISVILLE | KY | 40241-1086 | JEFFERSON | USA | UG3DA061620 | Registration Development Program for LUCEMYRA (Lofexidine) Label Expansion for Opioid Withdrawal Treatment in Adolescents | 001 | 1 | NIH | 7/18/2024 | $2,916,742 |
| | 2024 | 2024 | USWM LLC | 4441 SPRINGDALE RD | LOUISVILLE | KY | 40241-1086 | JEFFERSON | USA | UG3DA061620 | Registration Development Program for LUCEMYRA (Lofexidine) Label Expansion for Opioid Withdrawal Treatment in Adolescents | 001 | 1 | NIH | 7/18/2024 | -$2,916,742 |
| | 2024 | 2024 | USWM LLC | 4441 SPRINGDALE RD | LOUISVILLE | KY | 40241-1086 | JEFFERSON | USA | UG3DA061620 | Registration Development Program for LUCEMYRA (Lofexidine) Label Expansion for Opioid Withdrawal Treatment in Adolescents | 000 | 1 | NIH | 7/2/2024 | $2,916,742 |
| | 2024 | 2021 | USWM LLC | 4441 SPRINGDALE RD | LOUISVILLE | KY | 40241-1086 | JEFFERSON | USA | UG3DA054799 | Development of Lofexidine as a First-line Non-Opioid Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome | 000 | 1 | NIH | 8/30/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | USWM LLC | 4441 SPRINGDALE RD | LOUISVILLE | KY | 40241-1086 | JEFFERSON | USA | UG3DA054799 | Development of Lofexidine as a First-line Non-Opioid Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome | 000 | 1 | NIH | 5/10/2023 | $0 |
| | 2023 | 2021 | USWM LLC | 4441 SPRINGDALE RD | LOUISVILLE | KY | 40241-1086 | JEFFERSON | USA | UG3DA054799 | Development of Lofexidine as a First-line Non-Opioid Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome | 001 | 1 | NIH | 5/25/2023 | $0 |
| | 2023 | 2021 | USWM LLC | 4441 SPRINGDALE RD | LOUISVILLE | KY | 40241-1086 | JEFFERSON | USA | UG3DA054799 | Development of Lofexidine as a First-line Non-Opioid Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome | 002 | 1 | NIH | 9/13/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2021 | USWM, LLC | 4441 SPRINGDALE RD | LOUISVILLE | KY | 40241-1086 | JEFFERSON | USA | UG3DA054799 | Development of Lofexidine as a First-line Non-Opioid Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome | 000 | 1 | NIH | 1/21/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $5,353,314 ) |
| | 2021 | 2021 | USWM, LLC | 4441 SPRINGDALE RD | LOUISVILLE | KY | 40241-1086 | JEFFERSON | USA | UG3DA054799 | Development of Lofexidine as a First-line Non-Opioid Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome | 000 | 1 | NIH | 9/24/2021 | $5,353,314 |
|
|
